Misoprostol for second-trimester pregnancy termination in women with a prior cesarean delivery

Obstet Gynecol. 2005 Feb;105(2):352-6. doi: 10.1097/01.AOG.0000151996.16422.88.

Abstract

Objective: To evaluate the use of misoprostol in second-trimester abortion in women with prior cesarean deliveries.

Methods: A review of women with prior cesarean deliveries undergoing abortion at 14-28 weeks of gestation for a fetal anomaly over a 7.5-year period. Outcome data were compared with a contemporaneous cohort of women with unscarred uteri undergoing the same procedure. Misoprostol was used to induce abortion in all cases, and a variety of dosage regimens were used, the most frequent being 400 mug vaginally every 6 hours (71.3%).

Results: During the study period, 720 consecutive women underwent a second-trimester abortion for a fetal anomaly using misoprostol. One hundred one women (14%) had at least 1 prior cesarean delivery: 78 women had 1, 19 women had 2, and 4 women had 3 prior cesarean deliveries. Women with a prior cesarean birth were significantly older (30 years [interquartile range 26-35] versus 33 years [29-37], no cesarean delivery versus cesarean delivery, P = < .001) and of increased parity. The median gestational age at delivery was 19.4 weeks (interquartile range 18-20.7) versus 19.3 weeks (17.7-21), no cesarean delivery versus cesarean delivery, P = .48. The presence of a prior uterine scar did not impact upon abortion duration (16.6 hours [12.1-23.8] versus 14.5 hours [11.4-21.4], no cesarean delivery versus cesarean delivery, P = .07). No differences in blood loss, major hemorrhage, or blood transfusion occurred. There was no case of uterine rupture or hysterectomy.

Conclusion: In second-trimester abortion, the use of misoprostol in women with prior cesarean delivery was not associated with an excess of complications compared with women with unscarred uteri.

Level of evidence: II-2.

Publication types

  • Comparative Study

MeSH terms

  • Abortion, Therapeutic / methods*
  • Administration, Intravaginal
  • Adult
  • Case-Control Studies
  • Cesarean Section*
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Fetal Diseases / diagnostic imaging
  • Follow-Up Studies
  • Humans
  • Maternal Age
  • Misoprostol / therapeutic use*
  • Pregnancy
  • Pregnancy Outcome*
  • Pregnancy Trimester, Second
  • Probability
  • Registries
  • Risk Assessment
  • Treatment Outcome
  • Ultrasonography, Prenatal

Substances

  • Misoprostol